White Sox manager Tony La Russa, 76, pleads guilty to reckless driving and is sentenced to a day of home detention, a $1,400 fine, and community service following his February DUI arrest
White Sox manager Tony La Russa pleaded guilty to a misdemeanor charge of reckless driving stemming from his DUI arrest in the Phoenix last February
The 76-year-old was sentenced to one day of home detention, fined nearly $1,400 and is required to complete 20 hours of community service
His lawyer said La Russa underwent alcohol counseling after the arrest
La Russa, who was working for the Los Angeles Angels during spring training, allegedly ran his Lexus SUV into a curb in the Phoenix area on February 24
White Sox manager La Russa: Deep remorse over DUI case
bignewsnetwork.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bignewsnetwork.com Daily Mail and Mail on Sunday newspapers.
White Sox manager La Russa pleads guilty to reckless driving
austinglobe.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from austinglobe.com Daily Mail and Mail on Sunday newspapers.
The most shocking trade in baseball history had St Louis fans in an uproar
thesalemnewsonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thesalemnewsonline.com Daily Mail and Mail on Sunday newspapers.
Izotropic Corporation: Izotropic Reports High Degree of Confidence After Pre-Submission Meeting with FDA
Izotropic Corporation (CSE:
Izotropic or the
Company ) announces it has received the finalized meeting minutes from the U.S. Food and Drug Administration (FDA) in connection with the Company s recent pre-submission meeting and the market approval process for its commercial Breast CT Imaging System.
Dr. John McGraw, Executive Vice-President of Commercial Operations, stated, I am pleased to report that the meeting with the FDA was very beneficial for Izotropic and the comments received have validated our clinical study plan and development efforts to date. The initial indication for use for breast CT as a diagnostic device has been confirmed, and we have come away from the meeting with a high degree of confidence in our U.S. market approval plan moving forward.